Singapore markets closed

Straits Times Index
3,280.10
-7.65(-0.23%)
Nikkei
37,934.76
+306.28(+0.81%)
Hang Seng
17,651.15
+366.61(+2.12%)
FTSE 100
8,139.83
+60.97(+0.75%)
Bitcoin USD
63,678.29
+705.21(+1.12%)
CMC Crypto 200
1,346.06
-50.47(-3.61%)

CSL Limited (CSJ.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR

Add to watchlist

167.58

+0.68

(+0.41%)

At close: 09:41PM CEST

All

GlobeNewswire
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with p
PR Newswire
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
Simply Wall St.
CSL Limited (ASX:CSL) On An Uptrend: Could Fundamentals Be Driving The Stock?
CSL's (ASX:CSL) stock is up by 1.2% over the past month. We wonder if and what role the company's financials play in...